Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAS2R14 | Q9NYV8 | 12/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | PTGES | O14684 | 1/20 | 0.45 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.44 |
| ▸ | CXCR3 | P49682 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.43 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.43 |
| ▸ | SPPL2A | Q8TCT8 | 1/20 | 0.43 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.43 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.43 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.43 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3852814 | 0.87 | TAS2R14 (0.54) | TAS2R14LMNAPTGES | |
| SCHEMBL3850168 | 0.82 | LMNA (0.61) | TAS2R14LMNAPTGESKCNA5CXCR3 | |
| SCHEMBL3855849 | 0.80 | TAS2R14 (0.53) | TAS2R14LMNAMAPT | |
| SCHEMBL3851680 | 0.79 | TAS2R14 (0.74) | TAS2R14PTGESKCNA5 | |
| SCHEMBL3858873 | 0.79 | TAS2R14 (0.50) | TAS2R14LMNAKCNA5 | |
| SCHEMBL3848953 | 0.78 | CNR2 (0.62) | TAS2R14LMNAPTGES | |
| SCHEMBL3852199 | 0.78 | PDE4A (0.60) | TAS2R14LMNAPTGESMAPT | |
| SCHEMBL3855851 | 0.78 | TAS2R14 (0.54) | TAS2R14LMNAMAPT | |
| SCHEMBL5010585 | 0.77 | HTR2A (0.62) | LMNAMAPTPSEN1PSEN2SPPL2A | |
| SCHEMBL3858004 | 0.73 | TAS2R14 (0.49) | TAS2R14LMNAKCNA5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7579504-B2 | ABCA1 elevating compounds | GILEAD SCIENCES, INC. (US) | 2009-08-25 | — | — | US | disclosed |
| US-20070203245-A1 | ABCA1 elevating compounds | CV THERAPEUTICS, INC. | 2007-08-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070203245-A1 | ABCA1 elevating compounds | ABCD3, ABCB4, CETP | TAS2R14 4736/4885LMNA 830/4885PTGES 1136/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.